Post-COVID-19 cholangiopathy:Current understanding and management options  

作　　者：Fadl H Veerankutty Kushan Sengupta Mukul Vij Ashwin Rammohan Dinesh Jothimani Ananthavadivelu Murali Mohamed Rela 

机构地区：[1]Institute of Liver Disease and Transplantation,Dr.Rela Institute and Research Centre,Chennai 600044,India [2]Institute of Liver Disease and Transplantation,Dr.Rela Institute and Medical Centre,Chennai 600044,India [3]Department of Pathology,Institute of Liver Disease and Transplantation,Chennai 600044,India [4]Gastroenterology and Hepatology,Clinician’s Point,Chennai 600014,Tamil Nadu,India

出　　处：《World Journal of Gastrointestinal Surgery》2023年第5期788-798,共11页世界胃肠外科杂志（英文版）（电子版）

摘　　要：Post-coronavirus disease 2019(COVID-19)cholangiopathy(PCC)is a rare but lifethreatening complication of COVID-19 infection.PCC typically presents when patients recovering from the contagion and manifests as cholestasis in patients with no history of pre-existing liver disease.The pathogenesis of PCC is little understood.Hepatic injury in PCC could be mediated by the predilection of severe acute respiratory syndrome coronavirus 2 for cholangiocytes.Though PCC shows some resemblance to secondary sclerosing cholangitis in critically ill patients,it is considered as a separate and unique entity in the literature.Various treatment options like ursodeoxycholic acid,steroids,plasmapheresis,and endoscopic retrograde cholangiopancreatography guided interventions have been tried but with limited success.We have noticed significant improvement in liver function with antiplatelet therapy in a couple of patients.PCC can progress to end-stage liver disease necessitating liver transplantation.In this article,we discuss the current knowledge of PCC focusing on its pathophysiology,clinical manifestations,and management strategies.

关 键 词：COVID-19 Liver Post-COVID-19 syndrome Long haulers CHOLANGIOPATHY CHOLESTASIS 

分 类 号：R563.1[医药卫生—呼吸系统] R575.7[医药卫生—内科学]